Novartis' Lutathera Shows Promising Results in First-Line Treatment of Neuroendocrine Tumors

Novartis announced that its radioligand therapy Lutathera, in combination with long-acting octreotide, demonstrated a statistically significant improvement in progression-free survival (PFS) in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in a Phase III clinical trial. The trial met its primary endpoint of improved PFS and a key secondary endpoint of objective response rate. Lutathera is the first radioligand therapy to show clinically meaningful benefit in a first-line setting. The findings will be presented at an upcoming medical meeting and discussed with regulatory authorities. Novartis is also exploring the use of radioligand therapies in other advanced cancers and expanding its manufacturing capabilities to meet the increasing demand.